Dateline — CARLSBAD, Calif., November 11, 2025:
Exagen Inc. (Nasdaq: XGN), a leader in autoimmune diagnostics, has announced its participation in two major fourth-quarter investor conferences — the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, and the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on November 20, 2025. Both events, to be held in New York City, highlight Exagen’s growing role in precision diagnostics and its strategic focus on innovation, quality, and patient care within the regulated MedTech landscape.
Science Significance
Exagen’s participation underscores the scientific importance of precision testing in autoimmune disease management. Its flagship product, AVISE® CTD, represents a clinically validated leap forward in the early and accurate diagnosis of lupus, rheumatoid arthritis, and Sjögren’s disease. With a CLIA-certified and CAP-accredited laboratory, Exagen exemplifies how advanced immunodiagnostic technologies are reshaping disease identification and monitoring. The company’s focus on biomarker-driven testing enhances clinician decision-making and provides vital data to improve outcomes for patients with complex autoimmune conditions.
Regulatory Significance
From a regulatory and compliance perspective, Exagen operates under the stringent standards of CLIA (Clinical Laboratory Improvement Amendments) and CAP (College of American Pathologists), ensuring the accuracy, reproducibility, and integrity of its diagnostic results. These accreditations place Exagen squarely within the regulated MedTech environment, aligning with FDA quality expectations and industry best practices for diagnostic laboratories. Participation in high-profile investor conferences also signals Exagen’s commitment to maintaining transparency and compliance while pursuing innovation within a tightly controlled quality framework — a core value for any cGxP-focused entity.
Advertisement
Business Significance
From a business standpoint, Exagen’s involvement in the Q4 2025 investor forums marks a strategic engagement with the financial community amid a period of expanding diagnostic offerings. Investor conferences serve as pivotal venues for companies like Exagen to highlight pipeline developments, revenue performance, and strategic partnerships. The company’s consistent participation reinforces its market visibility, strengthens investor confidence, and positions Exagen as a growth-oriented player in the autoimmune diagnostics market. These events also provide a platform to showcase ongoing advancements in diagnostic technology, reimbursement models, and patient access strategies.
Patients’ Significance
For patients, particularly those battling chronic autoimmune diseases, the significance of Exagen’s innovations is profound. Earlier, more accurate diagnosis means improved treatment timelines and reduced disease burden. By offering clinicians data-rich, validated testing solutions, Exagen directly contributes to personalized care, reducing misdiagnosis and promoting proactive disease management. Its AVISE® suite helps transform uncertainty into clarity, empowering patients and healthcare professionals alike with actionable information — a crucial step toward improving quality of life for millions affected by autoimmune disorders.
Policy Significance
On the policy front, Exagen’s operational model aligns with the national emphasis on precision medicine, diagnostic stewardship, and laboratory quality compliance. The company’s participation in investor discussions can influence broader conversations around diagnostic regulation, reimbursement policies, and the integration of digital health into autoimmune disease management. With health systems increasingly focused on outcome-based diagnostics, Exagen stands as a benchmark for regulated innovation within U.S. MedTech and diagnostics policy frameworks.
Exagen’s proactive engagement in these Q4 2025 investor conferences not only highlights its leadership in autoimmune diagnostics but also reinforces its commitment to scientific excellence, regulatory integrity, and patient-centered innovation. As the company continues to expand its diagnostic portfolio and partnerships, Exagen remains a key player in advancing compliance-driven medical technology that bridges science, business, and policy to transform patient outcomes in autoimmune disease management.
Source: Exagen Inc. press release
